Bile acids and incretins as modulators of obesity-associated atherosclerosis

Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrijana Kirsch, Juergen Gindlhuber, Diana Zabini, Elena Osto
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1510148/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841558804938883072
author Andrijana Kirsch
Juergen Gindlhuber
Diana Zabini
Elena Osto
Elena Osto
author_facet Andrijana Kirsch
Juergen Gindlhuber
Diana Zabini
Elena Osto
Elena Osto
author_sort Andrijana Kirsch
collection DOAJ
description Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide. Bile acids (BAs) and incretins are gut hormones involved in digestion and absorption of fatty acids, and insulin secretion, respectively. In recent years BAs and incretins are increasingly recognized as key signaling molecules, which target multiple tissues and organs, beyond the gastro-intestinal system. Moreover, incretin-based therapy has revolutionized the treatment of T2DM and obesity. This mini review highlights the current knowledge about dysregulations in BA homeostasis in obesity with a special focus on atherosclerosis as well as athero-modulating roles of incretins and currently available incretin-based therapies.
format Article
id doaj-art-e8f002bc80df4557882f50b54dec61be
institution Kabale University
issn 2297-055X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj-art-e8f002bc80df4557882f50b54dec61be2025-01-06T05:13:19ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011110.3389/fcvm.2024.15101481510148Bile acids and incretins as modulators of obesity-associated atherosclerosisAndrijana Kirsch0Juergen Gindlhuber1Diana Zabini2Elena Osto3Elena Osto4Division of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaDivision of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaDivision of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaDivision of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaVetsuisse Faculty, University of Zurich, Zurich, SwitzerlandObesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide. Bile acids (BAs) and incretins are gut hormones involved in digestion and absorption of fatty acids, and insulin secretion, respectively. In recent years BAs and incretins are increasingly recognized as key signaling molecules, which target multiple tissues and organs, beyond the gastro-intestinal system. Moreover, incretin-based therapy has revolutionized the treatment of T2DM and obesity. This mini review highlights the current knowledge about dysregulations in BA homeostasis in obesity with a special focus on atherosclerosis as well as athero-modulating roles of incretins and currently available incretin-based therapies.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1510148/fullcardiovascular diseaseobesitygut hormoneslipoproteinsatherosclerosis
spellingShingle Andrijana Kirsch
Juergen Gindlhuber
Diana Zabini
Elena Osto
Elena Osto
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Frontiers in Cardiovascular Medicine
cardiovascular disease
obesity
gut hormones
lipoproteins
atherosclerosis
title Bile acids and incretins as modulators of obesity-associated atherosclerosis
title_full Bile acids and incretins as modulators of obesity-associated atherosclerosis
title_fullStr Bile acids and incretins as modulators of obesity-associated atherosclerosis
title_full_unstemmed Bile acids and incretins as modulators of obesity-associated atherosclerosis
title_short Bile acids and incretins as modulators of obesity-associated atherosclerosis
title_sort bile acids and incretins as modulators of obesity associated atherosclerosis
topic cardiovascular disease
obesity
gut hormones
lipoproteins
atherosclerosis
url https://www.frontiersin.org/articles/10.3389/fcvm.2024.1510148/full
work_keys_str_mv AT andrijanakirsch bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis
AT juergengindlhuber bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis
AT dianazabini bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis
AT elenaosto bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis
AT elenaosto bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis